Seventh patent as polymer delivery gains Canadian patent

By Andrew McDougall

- Last updated on GMT

Related tags: Patent

Research and development company Skinvisible has announced that the Canadian Patent Office has awarded its Invisicare polymer delivery technology a patent, allowing it to expand its portfolio globally following six other patents worldwide.

Invisicare is the core technology in Skinvisible's portfolio of products which consists of 36 formulated topical products including prescription, over-the-counter and cosmetic formulations.

"Being granted the Invisicare patent in Canada fortifies Skinvisible's global intellectual property portfolio,"​ said Terry Howlett, CEO of Skinvisible.

"It is a key strategic priority for Skinvisible to obtain patent coverage for our Invisicare technology as well as the unique product benefits that we discover during our research and development process."

The Las Vegas-based firm states the technology enhances delivery systems for topically applied skin care products such as water insoluble actives as well as certain cationic actives. The enhancement is derived by controlling the release of the actives, while also binding the products to the skin for an extended duration.

Protection in three key areas

The Canadian patent for Invisicare includes a total of 48 claims, protecting it in three key areas: Topical Composition, Topical Composition Precursor, and Methods for Manufacturing and Using.

"For Skinvisible, our patents are intrinsic to the overall value of our products we offer for licensing,”​ added Howlett.

Overall Skinvisible has 28 patents pending including 12 in the US and 16 international applications covering six patents.

This latest patent in Canada is the seventh comprehensive patent granted to Skinvisible internationally, and is equivalent to the patents already granted in Australia, China, Hong Kong, India, Japan and Korea for Invisicare.

Skinvisible also holds four United States patents which include one product patent and three patents relating to Invisicare.

Key investment in patent protection

"Patent protection represents a key investment for Skinvisible as it provides our products with long-term market exclusivity,"​ said Howlett after being granted the Hong Kong patent last year.

"Patents strengthen our ability to license our unique product formulations worldwide, as evidenced by our recent agreements in Europe, China and the United States. We are aggressively pursuing additional licensing opportunities for formulations developed with the Invisicare technology,"​ he explained.

Related news

Related products

show more

Tagra: Stabilizing Retinol to Rejuvenate Skin

Tagra: Stabilizing Retinol to Rejuvenate Skin

Tagra Biotechnologies | 03-Oct-2022 | Product Presentation

Retinol is widely regarded in the cosmetics industry as a golden ingredient for ageless skin. Yet, it tends to lose its efficacy quickly due to a variety...

Sensiva™ go natural,a protector without compromise

Sensiva™ go natural,a protector without compromise

Ashland Global Holdings Inc | 24-Jun-2022 | Technical / White Paper

Consumers are increasingly buying natural, organic beauty and wellbeing products as noted from the increasing number of product launches with natural claim...

Formulating for Clean Beauty

Formulating for Clean Beauty

Elementis | 26-May-2022 | Product Brochure

Water scarcity and water pollution continues to be a concern for the environment. Every year, about 130 tons of microplastic particles from personal care...

Follow us

Products

View more

Webinars

Indie Pioneers Podcast

Indie Pioneers Podcast